Search hospitals

>

Washington

>

Seattle

Fred Hutchinson Cancer Research Center

Claim this profile

Seattle, Washington 98109

Global Leader in Cancer

Global Leader in Leukemia

Conducts research for Breast Cancer

Conducts research for Lymphoma

Conducts research for Acute Myeloid Leukemia

818 reported clinical trials

105 medical researchers

Photo of Fred Hutchinson Cancer Research Center in SeattlePhoto of Fred Hutchinson Cancer Research Center in SeattlePhoto of Fred Hutchinson Cancer Research Center in Seattle

Summary

Fred Hutchinson Cancer Research Center is a medical facility located in Seattle, Washington. This center is recognized for care of Cancer, Leukemia, Breast Cancer, Lymphoma, Acute Myeloid Leukemia and other specialties. Fred Hutchinson Cancer Research Center is involved with conducting 818 clinical trials across 1,001 conditions. There are 105 research doctors associated with this hospital, such as Michael J Wagner, MD, Michael Schweizer, Christina S. Baik, and Jennifer M. Specht.

Area of expertise

1

Cancer

Global Leader

Fred Hutchinson Cancer Research Center has run 214 trials for Cancer. Some of their research focus areas include:

Stage IV
Stage III
HER2 positive
2

Leukemia

Global Leader

Fred Hutchinson Cancer Research Center has run 209 trials for Leukemia. Some of their research focus areas include:

HLA-A positive
HLA-A negative
RB1 positive

Top PIs

Clinical Trials running at Fred Hutchinson Cancer Research Center

Breast Cancer

Prostate Cancer

Ovarian Cancer

Breast cancer

Multiple Myeloma

Chronic Lymphocytic Leukemia

Pancreatic Cancer

Follicular Lymphoma

Non-Hodgkin's Lymphoma

Colorectal Cancer

Image of trial facility.

Letrozole

for Breast Cancer

This stage IV trial examines how a mutation in HSD3B1 (1245C) gene affects treatment of stage I-III breast cancer. This trial may help researchers determine if mutations in HSD3B1 decreases the efficacy of aromatase inhibitor therapy such as letrozole. Letrozole may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Recruiting

3 awards

Phase 4

10 criteria

Image of trial facility.

Chemotherapy + Hormone Therapy

for Breast Cancer

This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.

Recruiting

2 awards

Phase 3

19 criteria

Image of trial facility.

Low Dose Tamoxifen

for Breast Cancer

This phase III trial compares the effect of low dose tamoxifen to usual hormonal therapy, including aromatase inhibitors, in treating post-menopausal women with hormone positive, HER2 negative early stage breast cancer. Tamoxifen is in a class of medications known as antiestrogens. It blocks the activity of estrogen (a female hormone) in the breast. This may stop the growth of some breast tumors that need estrogen to grow. Aromatase inhibitors, such as anastrozole, letrozole, and exemestane, prevent the formation of estradiol, a female hormone, by interfering with an aromatase enzyme. Aromatase inhibitors are used as a type of hormone therapy to treat postmenopausal women with hormone-dependent breast cancer. Giving low dose tamoxifen may be more effective compared to usual hormone therapy in treating post-menopausal women with hormone-positive, HER2 negative early stage breast cancer.

Recruiting

2 awards

Phase 3

8 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Fred Hutchinson Cancer Research Center?

Where is Fred Hutchinson Cancer Research Center located?

Who should I call to ask about financial aid or insurance network?

What insurance does Fred Hutchinson Cancer Research Center accept?

What awards or recognition has Fred Hutchinson Cancer Research Center received?